Meghana Keshavan covers biotech and contributes to The Readout newsletter . Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Radiopharma’s precision promise runs into toxicity problems, China puts new guardrails around its biotech innovation engine, and Grail’s Galleri heads to an FDA advisory panel. AdvertisementThis Readout was partially produced at a sun-splashed kiddie pool party in SoCal.